Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03217968 · ClinicalTrials.gov registry record · NA
Abortive Treatment of Migraine With the Cefaly® Abortive Program Device
A NA study of Migraine, sponsored by Cefaly Technology.
- Completed
- Registry status
- NA
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT03217968: Completed NA study of Migraine, sponsored by Cefaly Technology.
NCT03217968 is a NA study of Migraine that has completed, run by Cefaly Technology. The registered enrollment target is 59 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03217968, a NA study of Migraine, has completed, sponsored by Cefaly Technology.
- COMPLETED
- Registry status
- NA
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack. This open clinical trial will study the abortive treatment of migraine using the Cefaly® Abortive Program device, prior to development of a sham-controlled trial.
Primary Outcome
The percentage of patients having a reduction of a moderate or severe migraine headache (Grade 2 or 3) at baseline to no headache (Grade 0) at 2 hours after the beginning of the e-TNS session.
Conditions Studied
Interventions
- DEVICE Cefaly® Abortive Program device
Study Locations (1)
New York
- Rochester Clinical Research, Inc. - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2017-08-10 |
| Est. Completion | 2018-01-10 |
| Phase | NA |
What the finished NCT03217968 record still lists
NCT03217968 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Cefaly® Abortive Program device is the first listed.
NCT03217968 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03217968 about?
NCT03217968 is a clinical study titled "Abortive Treatment of Migraine With the Cefaly® Abortive Program Device". The purpose of this study is to investigate the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack. This open clinical trial will study the abortive treatment of migraine using the Cefaly® Abortive Program device, prior to development of a sham-contro...
What is the current status of trial NCT03217968?
This trial is currently completed. It is a NA study. The enrollment target is 59 participants. The study started on 2017-08-10. Estimated completion is 2018-01-10.
What conditions does trial NCT03217968 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT03217968?
The interventions under investigation include: Cefaly® Abortive Program device (DEVICE).
Who is sponsoring clinical trial NCT03217968?
This trial is sponsored by Cefaly Technology, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03217968 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03217968's enrollment target sits among peer trials
59 79th of 102 higher than 24 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
-
Cocoa Extract for Migraine Trial
RECRUITING · NA
-
Migraine in Adolescents
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI